Customize your JAMA Network experience by selecting one or more topics from the list below.
This has been a terrific year for JAMA Oncology. Our debut impact factor of 16.56 placed us as one of the highest-ranking oncology journals. JAMA Oncology published 30 of the top 50 papers among oncology journals as measured by Altmetric. We would like to thank our authors, reviewers, and readers for the significant contributions made to the journal this past year. The editorial board and I are honored to have the opportunity to serve the oncology community by offering original, innovative, and timely scientific content that has a direct impact on researchers, clinicians, and the patients we serve.
I would like to thank our authors. In 2017, we published 373 total articles including 112 Original Investigations, 31 Viewpoints, and 4 Special Communications. The quality of our published articles is reflected in the 1.7 million downloads of articles from our site and the more than 7500 media mentions of JAMA Oncology articles in print, online, and news services this past year. Choosing papers for the journal was challenging. We received a total of 2083 manuscript submissions in 2017—an impressive 21% increase in submissions from the year prior. These submissions to JAMA Oncology included 1253 Original Investigations, 143 Clinical Trial reports, 138 Meta-analyses, and 73 Reviews.
In 2017, the overall acceptance rate was 11%. Our acceptance rate for Original Investigations was 5%, 18% for Clinical Trials, and 6% for Meta-analyses. We accepted 7% of Review articles, 19% of submitted Research Letters, 20% of Viewpoints, and 23% of Clinical Challenges. JAMA Oncology is indexed in PubMed, MEDLINE, and Thomson Reuters’ Science Citation. More detailed statistics about our content are displayed in the Table.
We are also very grateful to our global consortium of peer reviewers who contributed to the journal this year.1 We are pleased to acknowledge their contribution to JAMA Oncology by publishing the names of the more than 880 experts who completed a manuscript review in 2017. This group of renowned laboratory, clinical, quantitative, and statistical scientists provided comprehensive reviews of the submitted manuscripts in a median of just 13 days. Their timely and high-quality work for the journal has allowed JAMA Oncology to maintain a median time from receipt of a manuscript to acceptance of an impressive 28 days. The ability to rapidly review and return a decision on our submissions within 4 weeks of submission ensures that authors receive a detailed and efficient service in reviewing their work, and that those important findings are available to the oncology community as quickly as possible. We would not be able to provide this service without our expert peer reviewers and their commitment to providing prompt and high-quality reviews for the journal.
Finally, we would like to thank our readers. Print copies of JAMA Oncology are distributed to approximately 15 000 recipients each month, and we provide our Table of Contents of newly published material each week, by email, to 28 698 readers. We are proud to continue offering the most innovative, provocative, and timely research for scientists, clinicians, and trainees in the field of oncology worldwide. We encourage our readers to stay involved with the journal by submitting Letters to the Editor and offering recommendations for new topics that you would like to see covered in future issues. Your suggestions make this interdisciplinary oncology journal dynamic and current—keep them coming!
We have truly enjoyed being involved in JAMA Oncology’s continued success this year, and we look forward to the year ahead. We could not have done it without you. We invite all of our readers to sign up for email Table of Contents at http://www.jamaoncology.com, follow us on Twitter @JAMAOnc, or friend us on Facebook. We will keep you up to date on the most important discoveries influencing cancer care.
Corresponding Author: Mary L. (Nora) Disis, MD, University of Washington and Fred Hutchinson Cancer Research Center, 850 Republican St, Brotman 221, PO Box 358050, Seattle, WA 98195-8050 (firstname.lastname@example.org).
Published Online: March 8, 2018. doi:10.1001/jamaoncol.2017.5108
Conflict of Interest Disclosures: None reported.
Disis ML(. JAMA Oncology—The Year in Review, 2017. JAMA Oncol. Published online March 08, 2018. doi:10.1001/jamaoncol.2017.5108